Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT02772588 2026-01-27

AASUR in High Risk Prostate Cancer

Phase 2 Completed

64 enrolled

Genitourinary

Prostatic Neoplasms

NCT03556904 2026-01-15

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Phase 2 Completed

14 enrolled 16 charts

Genitourinary

Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT06384222 2025-12-30

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

Phase 2 Recruiting

32 enrolled

Genitourinary

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

532 enrolled

Genitourinary

Prostatic Neoplasms

NCT07299292 2025-12-23

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

Phase 2 Recruiting

60 enrolled

Genitourinary

Disease, Prostatic Neoplasms

Clinical Trials

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

InavoPC

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Tamarack

AASUR in High Risk Prostate Cancer

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

DIVINE

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)